Abiraterone Acetate Tablet
Product Images NDC 71921-178

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 71921-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Florida Pharmaceutical Products, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (01)

Chemical structure of abiraterone acetate, showing its molecular framework including acetate and steroid-related rings with associated methyl groups and a pyridine ring.*

FDA Label Image

Figure 1 (02)

A Kaplan-Meier survival curve graph comparing % survival over time in months for abiraterone acetate versus placebo. The chart shows two distinct survival lines with abiraterone acetate having a higher survival rate than placebo. The x-axis is labeled 'Time to death, months' and the y-axis is labeled '% Survival.' The number of subjects at risk for each group is tabulated below the graph across different time points.*

FDA Label Image

Figure 2 (03)

A Kaplan-Meier survival curve chart illustrating the percentage of subjects without death over time, comparing abiraterone acetate versus placebo. The x-axis shows months from randomization (0 to 60), and the y-axis indicates the percentage of subjects without death (0 to 100%). Two lines represent survival for placebo (dashed) and abiraterone acetate (solid). The numbers at risk are displayed below the x-axis for both groups.*

FDA Label Image

Figure 3 (04)

A Kaplan-Meier survival curve chart depicting the percentage of subjects without radiographic progression or death over time (months from randomization) for abiraterone acetate tablets (250 mg) compared to placebo. The chart includes the number of subjects at risk at various time points for both treatment groups.*

FDA Label Image

Figure 4 (05)

A Kaplan-Meier survival curve depicting % survival of subjects without death over months from randomization, comparing abiraterone acetate versus placebo. The graph includes data points and survival trends for both groups, with subject risk counts shown below the x-axis at multiple time points from 0 to 66 months.*

FDA Label Image

Principal Display Panel (250 mg Tablet Bottle Label)

Label for Abiraterone Acetate tablets, USP 250 mg, oral dosage form, containing 120 tablets per package. The label includes warnings, storage instructions, manufacturer information (Qilu Pharmaceutical Co., Ltd., China), and distributor details (Florida Pharmaceutical Products, LLC, Boca Raton, FL). It features a barcode and a warning for women who are or may be pregnant.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.